Neuphoria Therapeutics Inc
Company Details
Status: Public
Employees: 11-50
Location:
100 Summit Dr, Burlington, Massachusetts 01803, US
Type:
sample
sample
Technology:
sample
About: Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Burlington, Massachusetts. Formerly known as Bionomics Limited, the company focuses on developing innovative therapies for neuropsychiatric disorders and cancers. Neuphoria was incorporated in 1996 and rebranded in December 2024.
The company's lead product candidate, BNC210, is a selective negative allosteric modulator aimed at treating social anxiety disorder and post-traumatic stress disorder (PTSD). BNC210 is currently in Phase 3 and Phase 2b clinical trials, respectively. Other products in development include BNC101, a monoclonal antibody for cancer stem cells, and BNC105, which targets refractory colorectal cancer and chronic lymphocytic leukemia. Neuphoria is also exploring treatments for cognitive deficits in schizophrenia and autism spectrum disorders, as well as chronic pain management without opioid addiction. The company has partnered with Merck & Co., Inc. to develop therapies for cognitive dysfunction related to Alzheimer's disease and other central nervous system conditions.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Neuphoria Therapeutics Inc | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.